Skip to main content
IM

ImmVirX

New Lambton, Australia
Last funding
$25.0M
Series BJun 2023

ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.

Backed byOneVenturesAcorn Capital

About ImmVirX

How much funding has ImmVirX raised?

ImmVirX has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.

Who are ImmVirX's investors?

ImmVirX's investors include OneVentures, Acorn Capital.

Where is ImmVirX headquartered?

ImmVirX is headquartered in New Lambton, Australia.

What does ImmVirX do?

ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.

What stage is ImmVirX at?

ImmVirX is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"ImmVirX — Funding & Investors." VCBacked, June 5, 2023, https://www.vcbacked.co/company/immvirx. Accessed November 15, 2026.
APA
VCBacked. (2023). ImmVirX — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/immvirx
Wikipedia (cite web)
{{cite web |title=ImmVirX — Funding & Investors |url=https://www.vcbacked.co/company/immvirx |website=VCBacked |access-date=November 15, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at ImmVirX? Request a listing update

Founder contacts
m***@immvirx.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →